Bio Pharma Dive
FEBRUARY 7, 2024
The new firm intends to carefully select its startups and fund them for the long haul. “We're not a company formation factory,” said Aaron Kantoff, the firm’s co-founder.
Pharmaceutical Technology
FEBRUARY 7, 2024
Gilead Sciences has announced a 22.9% increase in net income of $5.61bn for FY23 as against $4.56bn in FY22.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 7, 2024
People with bipolar disorder are four to six times more likely to die prematurely than those without the condition, according to a study that compared data on thousands of people with and without the disorder.
Pharmaceutical Technology
FEBRUARY 7, 2024
AstraZeneca is investing $300m in a facility in Rockville, US - a significant step in launching its cell therapy platforms in the country.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
FEBRUARY 7, 2024
The company, a leading developer of cell therapies for autoimmune diseases, is the fifth drug startup to go public in 2024. All of them raised at least $100 million.
Pharmaceutical Technology
FEBRUARY 7, 2024
Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
FEBRUARY 7, 2024
Ligelizumab is under clinical development by Novartis and currently in Phase III for Food Allergy.
Bio Pharma Dive
FEBRUARY 7, 2024
The deal hands Kyowa Kirin rights in Japan to the drug, which is emerging as a potential rival to BioMarin’s marketed medicine Voxzogo.
Pharmaceutical Technology
FEBRUARY 7, 2024
(Sacubitril + valsartan) is under clinical development by Novartis and currently in Phase II for Hypertrophic Cardiomyopathy.
Rethinking Clinical Trials
FEBRUARY 7, 2024
In this Friday’s PCT Grand Rounds, Cynthia Hau of the VA Boston Health Care System will present “Pragmatic Recruitment of Underrepresented Groups: Experience From the Diuretic Comparison Project.” The Grand Rounds session will be held on Friday, February 9, 2024, at 1:00 pm eastern. Hau is a statistician for the VA Cooperative Studies Program Coordinating Center in the VA Boston Health Care System.
Pharmaceutical Technology
FEBRUARY 7, 2024
Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
Bio Pharma Dive
FEBRUARY 7, 2024
The UK drugmaker is adding a facility in Rockville, Maryland, after a spate of dealmaking in the therapeutic field.
Pharmaceutical Technology
FEBRUARY 7, 2024
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Neuroendocrine Carcinoma.
Bio Pharma Dive
FEBRUARY 7, 2024
Analysts pressed company executives Tuesday on the potential of its GLP-1 drug for weight loss, early-stage results for which were published this week.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
FEBRUARY 7, 2024
Veru’s Ostarine has previously been investigated in five clinical studies in patients with muscle wastage caused by advanced cancer.
Pharma Times
FEBRUARY 7, 2024
The HTA reported that Brainomix 360 improved access to treatment for stroke patients
Pharmaceutical Technology
FEBRUARY 7, 2024
The acquisition, which also includes Phase II asset AL101, closes gap to SpringWorks’ FDA-approved Ogsiveo.
Rethinking Clinical Trials
FEBRUARY 7, 2024
Speaker Susan C. Winckler, RPh, Esq Chief Executive Officer Reagan-Udall Foundation for the FDA Slides Keywords U.S. Food and Drug Administration, FDA, Misinformation, Communication, Health Information Key Points U.S. Food and Drug Administration (FDA) Commissioner Robert Califf asked the Reagan-Udall Foundation to conduct research and consult with experts to better understand how consumers find, consume, and perceive health information, especially regarding FDA-regulated
Pharmaceutical Technology
FEBRUARY 7, 2024
Jazz Pharmaceuticals has agreed to acquire rights for a KRAS inhibitor programme from Redx Pharma, in a deal totalling $880m.
Pharma Times
FEBRUARY 7, 2024
The new products are in the areas of gastrointestinal and respiratory medicines
Pharmaceutical Technology
FEBRUARY 7, 2024
Stalicla closes a successful Series B financing round and sets sights on Series C as interest stirs for CNS disorder deals.
pharmaphorum
FEBRUARY 7, 2024
In this interview, Simon Arkell, co-founder and CEO of Ryght, discusses his vision whilst at JP Morgan 2024 and how generative AI is transforming the industry.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
FEBRUARY 7, 2024
Eli Lilly has announced $2.19bn as net income on a reported basis for the fourth quarter of 2023, marking a 13% rise.
pharmaphorum
FEBRUARY 7, 2024
Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into targeted cancer therapies. Under the terms of the deal, Jazz will acquire Redx’s KRAS inhibitor programme outright, including multiple preclinical-stage drug candidates, and will take responsibility for ushering the most promising compounds through clinical trials and onto the market.
Pharmaceutical Technology
FEBRUARY 7, 2024
When consent management processes are disconnected or poorly managed, it can have a detrimental impact on patient experiences.
Fierce Pharma
FEBRUARY 7, 2024
Despite markedly slower cell therapy growth from the third to the fourth quarter of 2023—and a recent setback for Trodelvy—historically HIV-focused Gilead Sciences is not discouraged amid its | Despite a tame level of fourth-quarter growth, recent advances should drive long-term cell therapy sustainability, Gilead execs said. Overall, the company is pushing to generate 30% of its revenues from oncology by 2030.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
FEBRUARY 7, 2024
The US FDA has accepted for review an sBLA to expand the usage of GSK’s RSV vaccine, Arexvy, in adults aged 50-59 years.
pharmaphorum
FEBRUARY 7, 2024
As the pandemic recedes and the global economy stabilises, are there promising signs for the biotech industry's financial outlook in 2024? Learn more about the potential for recovery, reducing bankruptcies, and attracting investors.
FDA Law Blog
FEBRUARY 7, 2024
By John A. Gilbert — Last week, DEA and DOJ announced a $59 million civil penalty settlement with eBay related to the failure to comply with Controlled Substances Act (CSA) requirements for identifying purchasers, maintaining records, and filing reports of individuals selling/purchasing pill presses and encapsulating machines. As stated in the press release , this was the fourth largest civil penalty settlement under the CSA and, ironically, did not involve the sale or distribution of any contr
pharmaphorum
FEBRUARY 7, 2024
Stay updated on the latest clinical trials happening from January 15th to January 19th, 2024. Explore trials by ExeVir, NurixTx, Synendos Therapeutics, and Oxford BioTx.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
324 
Let's personalize your content